Assessment of TNF-α inhibitors in airway involvement of relapsing polychondritis: A systematic review

5Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Relapsing polychondritis (RP) is a rare immune-mediated disease affecting cartilaginous structures. Respiratory tract manifestations are frequent and constitute a major cause of morbidity and mortality. The present review of the literature was designed to assess the efficacy of tumor necrosis factor alpha (TNF-α) inhibitors in respiratory tract involvement of RP.A MEDLINE literature search was performed from January 2000 to December 2016 to identify all studies and case reports of anti-TNF-α therapy in RP. Articles published in English or French concerning patients with respiratory tract involvement were eligible. Two authors (JB, FL) independently reviewed and extracted data concerning each patient and 2 personal cases were added. Treatment efficacy was assessed according to systemic and/or respiratory criteria.A total of 28 patients (mean age: 41.6 years; 16 females/12 males) were included in the final analysis. Anti-TNF-α therapy was associated with improved health status and respiratory symptoms in 67.8% and 60.1% of cases, respectively.These results suggest that TNF-α inhibitors could be considered for the treatment of respiratory tract involvement of RP.

Cite

CITATION STYLE

APA

Biya, J., Dury, S., Perotin, J. M., Launois, C., Dewolf, M., Deslée, G., & Lebargy, F. (2019). Assessment of TNF-α inhibitors in airway involvement of relapsing polychondritis: A systematic review. Medicine, 98(44), e17768. https://doi.org/10.1097/MD.0000000000017768

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free